In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”

Bibliographic Details
Main Authors:	H. Mohan, M. Guzman Lenis, E.Y. Laurette, O. Tejada, T. Sanghvi, K.-Y. Leung, L.S. Cahill, J.G. Sled, P. Delgado-Olguín, N.D.E. Greene, A.J. Copp, L. Serghides
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396421001274

id	doaj-3776b9db630946b1be7f30da0a6212e3
record_format	Article
spelling	doaj-3776b9db630946b1be7f30da0a6212e32021-04-30T07:22:54ZengElsevierEBioMedicine2352-39642021-04-0166103334In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”H. Mohan0M. Guzman Lenis1E.Y. Laurette2O. Tejada3T. Sanghvi4K.-Y. Leung5L.S. Cahill6J.G. Sled7P. Delgado-Olguín8N.D.E. Greene9A.J. Copp10L. Serghides11Toronto General Hospital Research Institute, University Health Network, Toronto, CanadaToronto General Hospital Research Institute, University Health Network, Toronto, CanadaToronto General Hospital Research Institute, University Health Network, Toronto, CanadaToronto General Hospital Research Institute, University Health Network, Toronto, CanadaToronto General Hospital Research Institute, University Health Network, Toronto, CanadaDevelopmental Biology & Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UKMouse Imaging Centre, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Chemistry, Memorial University of Newfoundland, St John's, Newfoundland and Labrador, CanadaMouse Imaging Centre, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Translational Medicine, The Hospital for Sick Children, Toronto, Ontario M5G 0A4, CanadaTranslational Medicine, The Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada; Heart & Stroke Richard Lewar Centre of Excellence, Toronto, Ontario M5S 3H2, CanadaDevelopmental Biology & Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UKDevelopmental Biology & Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UKToronto General Hospital Research Institute, University Health Network, Toronto, Canada; Department of Immunology and Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Corresponding author at: 101 College Street, 10-359, Toronto, Ontario, M5G 1L7, Canada.http://www.sciencedirect.com/science/article/pii/S2352396421001274
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	H. Mohan M. Guzman Lenis E.Y. Laurette O. Tejada T. Sanghvi K.-Y. Leung L.S. Cahill J.G. Sled P. Delgado-Olguín N.D.E. Greene A.J. Copp L. Serghides
spellingShingle	H. Mohan M. Guzman Lenis E.Y. Laurette O. Tejada T. Sanghvi K.-Y. Leung L.S. Cahill J.G. Sled P. Delgado-Olguín N.D.E. Greene A.J. Copp L. Serghides In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels” EBioMedicine
author_facet	H. Mohan M. Guzman Lenis E.Y. Laurette O. Tejada T. Sanghvi K.-Y. Leung L.S. Cahill J.G. Sled P. Delgado-Olguín N.D.E. Greene A.J. Copp L. Serghides
author_sort	H. Mohan
title	In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”
title_short	In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”
title_full	In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”
title_fullStr	In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”
title_full_unstemmed	In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”
title_sort	in response to the letter to the editor by romach et al. re our publication “dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”
publisher	Elsevier
series	EBioMedicine
issn	2352-3964
publishDate	2021-04-01
url	http://www.sciencedirect.com/science/article/pii/S2352396421001274
work_keys_str_mv	AT hmohan inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT mguzmanlenis inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT eylaurette inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT otejada inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT tsanghvi inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT kyleung inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT lscahill inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT jgsled inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT pdelgadoolguin inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT ndegreene inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT ajcopp inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels AT lserghides inresponsetothelettertotheeditorbyromachetalreourpublicationdolutegravirinpregnantmiceisassociatedwithincreasedratesoffetaldefectsattherapeuticbutnotatsupratherapeuticlevels
_version_	1721498579688751104

In response to the Letter to the Editor by Romach et al. re our publication “Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels”

Similar Items